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Multiple sclerosis (MS) is an inflammatory disorder affecting the brain and spinal cord. Major hallmarks of MS typically include
inflammation, demyelination and axon degeneration, although recent studies have also implicated synaptic dysfunction and
degeneration in disease pathogenesis. The discovery that treatment with the orally active immunomodulatory drug
fingolimod (FTY720) confers benefits in animal models and human patients has opened up new avenues for the treatment of
MS. In the present issue of the BJP, Rossi and colleagues used a mouse model of MS [experimental autoimmune
encephalomyelitis (EAE)] to provide new evidence suggesting that fingolimod may target MS symptoms, at least in part, by
ameliorating synaptic dysfunction. They demonstrated that fingolimod reversed modifications in glutamatergic transmission
found in the striatum of EAE mice, accompanied by a reduction in the severity of dendritic spine loss. This report suggests
that fingolimod treatment can have beneficial effects on synaptic pathology in MS, raising the intriguing possibility that
fingolimod treatment may also be advantageous in other diseases of the nervous system where inflammation and synaptic
pathology contribute to disease pathogenesis.
LINKED ARTICLE
This article is a commentary on Rossi et al., pp. 861–869 of this issue. To view this paper visit http://dx.doi.org/10.1111/
j.1476-5381.2011.01579.x
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Multiple sclerosis (MS) is classically characterized as an
inflammatory disorder of the central nervous system, target-
ing regions of both the brain and spinal cord (Compston and
Coles, 2008). The major pathological hallmarks to be found
in MS patients typically include inflammation, demyelina-
tion and axon degeneration (Compston and Coles, 2008;
Dutta and Trapp, 2011). The development of animal models
of MS, such as mice with experimental autoimmune encepha-
lomyelitis (EAE), has facilitated additional in-depth investi-
gations into pathological changes occurring during the early
stages of disease onset and progression. One notable result of
such studies has been the demonstration of synaptic pathol-
ogy occurring during the early stages of disease. For example,
initial studies demonstrated that glutamate excitotoxicity is a
significant event in EAE mice, and can be prevented with
AMPA/kainate antagonists (Pitt et al., 2000; Smith et al.,
2000). Later studies revealed that synapses, known to be
particularly vulnerable to excitotoxicity, become dysfunc-
tional and undergo degeneration in EAE mice (Zhu et al.,
2003; Centonze et al., 2009), potentially accounting for
several of the clinical symptoms of MS, including cognitive
deficits (Mandolesi et al., 2010). However, the precise order
and relationship of pathological events occurring in MS
remains the subject of intense debate (Compston and Coles,
2008; Dutta and Trapp, 2011).
Given that inflammation is a key event in MS pathogen-
esis, a significant amount of research effort has been directed
at developing immunomodulatory drugs as a treatment for
human patients. Fingolimod (FTY720) is one such immuno-
modulatory drug, shown to be highly effective in clinical
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trials for MS (Khatri et al., 2011). As a result, in 2010 fingoli-
mod was approved by the US Food and Drug Administration
for use in patients with relapsing forms of MS. Fingolimod is
a sphingosine 1-phosphate (S1P) receptor modulator that is
capable of crossing the blood–brain barrier (for review, see
Brinkmann, 2009). Its lipophilic nature and wide distribution
following oral administration make it an ideal drug to target
S1P receptors across a range of cell types in the nervous
system (including neurons and glial cells), resulting in the
prevention of lymphocyte invasion in MS (Brinkmann,
2009). However, the precise mechanism through which fin-
golimod confers neuroprotection in MS remains unclear (for
review, see Cohen and Chun, 2011).
In the current issue of the British Journal of Pharmacology,
Rossi et al. (2011) have provided us with potentially impor-
tant new insights into the mechanisms through which
fingolimod attenuates neurodegenerative events in an
established EAE mouse model of MS. Several studies have
demonstrated that fingolimod can confer neuroprotective
properties in EAE mice (for review, see Cohen and Chun,
2011). The new study builds on this previous knowledge by
showing that fingolimod can significantly ameliorate synap-
tic dysfunction in EAE mice in vivo. Rossi et al. (2011) used
established electrophysiological techniques (e.g. whole-cell
patch clamp recordings) to demonstrate that oral administra-
tion (0.3 mg·kg-1) of fingolimod reversed the increased dura-
tion and frequency of glutamate-mediated spontaneous
excitatory postsynaptic currents observed in EAE mice.
However, abnormal functioning of the axonal Na+/Ca2+
exchanger in EAE mice appeared to be unaltered by fingoli-
mod treatment, suggesting a synapse-specific element to
fingolimod-related neuroprotection. Importantly, fingolimod
did not alter any of the major physiological parameters of
basal synaptic transmission in healthy intact synapses, dem-
onstrating that it only has effects on synapses undergoing
pathological changes.
Alongside the reversal of functional synaptic deficits in
EAE mice, Rossi et al. (2011) demonstrated morphological
preservation of dendritic spines on striatal neurons when
treated with fingolimod, indicating structural, as well as func-
tional, preservation of synapses. Rossi et al. (2011) did not
perform any morphological studies of presynaptic markers in
their treated and untreated EAE mice (e.g. immunohis-
tochemical labelling of a synaptic vesicle marker such as
synaptobrevin or an active zone protein such as bassoon, or
electron microscopy). Thus, it remains to be firmly estab-
lished whether degeneration and loss of pre-synaptic nerve
terminals previously reported in EAE mice (Zhu et al., 2003)
were also attenuated by fingolimod. The Rossi et al. (2011)
study was confined to synapses in the striatum of EAE mice.
However, the potentially exciting nature of their findings
suggests that a more widespread spatial and temporal study of
synaptic pathology in other regions of the brain and spinal
cord is now warranted, in order to establish the extent of
synaptic protection conferred. Such studies will demonstrate
the extent to which amelioration of gross neurodegenerative
changes in EAE mice correlates directly with prevention of
synaptic pathology in vivo. Unfortunately, it is not technically
feasible at present to reliably and sensitively measure synaptic
integrity, function and/or density in the CNS of humans
using imaging techniques, so it is not possible to validate the
current findings from EAE mice in early- and mid-
symptomatic human MS patients treated with fingolimod.
Given that animal EAE models are thought to differ in some
aspects from MS in humans (Sriram and Steiner, 2005), such
studies in human patients may ultimately be required to
confirm the contribution of synaptic pathology to the patho-
genesis of MS and the potential for fingolimod to delay
disease progression by targeting synapses.
Perhaps most excitingly, from the wider perspective, the
current study potentially opens up new therapeutic avenues
for neurodegenerative conditions other than MS: it is con-
ceivable that fingolimod may be capable of conferring neu-
roprotection in other diseases of the nervous system where
inflammation and synaptic pathology contribute to disease
pathogenesis. Synaptic pathology is an important and early
event in many neurodegenerative conditions affecting both
the central and peripheral nervous systems (for review, see
Wishart et al., 2006). For example, synaptic dysfunction and
loss is widely considered to contribute directly to the patho-
genesis of Alzheimer’s disease, and is one of the best patho-
logical correlates of cognitive decline in human patients
(Coleman et al., 2004). Similarly, synaptic degeneration at the
neuromuscular junction is an early pathological hallmark in
many motor neuron diseases, including amyotrophic lateral
sclerosis and spinal muscular atrophy (Fischer et al., 2004;
Murray et al., 2008). The ability to directly target neuropro-
tective strategies to the synapse during early stages of neuro-
degeneration is therefore much sought after, with the Rossi
et al. (2011) study demonstrating that it can be achieved, at
least in mouse models, through oral drug delivery. Increased
levels of neuroinflammation have also been reported to occur
in all three of the diseases detailed above (Hensley, 2010;
Papadimitriou et al., 2010). Thus, whether fingolimod pro-
tects synapses directly (as may be suggested by the axonal
Na+/Ca2+ exchanger data in the Rossi study), or as a secondary
consequence of an effect on levels of inflammation, may not
be important. The findings of the Rossi et al. (2011) study are
therefore likely to be sufficient to encourage others to inves-
tigate whether fingolimod has the capability to ameliorate
synaptic pathology across a range of different neurodegenera-
tive conditions.
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